paclitaxel has been researched along with Bone Marrow Diseases in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (66.67) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, Y; Shu, Y; Xu, Q | 1 |
| Avezza, F; Bossi, M; Canta, A; Carozzi, V; Cavaletti, G; Ceresa, C; Chiorazzi, A; Crippa, L; Gilardini, A; Nicolini, G; Oggioni, N; Rodriguez-Menendez, V | 1 |
| Ganti, AK; Kessinger, A; Loberiza, FR | 1 |
| Ding, D; Kong, WM | 1 |
| Adamo, DO; Bicher, A; Christian, M; Davis, P; Kohn, EC; Link, C; Ognibene, FP; Rothenberg, M; Sarosy, G; Steinberg, SM | 1 |
| Alberti, D; Arzoomanian, R; Feierabend, C; Schiller, JH; Spriggs, D; Storer, B; Tutsch, K | 1 |
| Adamo, DO; Bicher, A; Christian, M; Davis, P; Jacob, J; Kohn, E; Reed, E; Sarosy, G | 1 |
| Crown, JP; Currie, V; Gilewski, TA; Hakes, TB; Heelan, R; Hudis, CA; Lebwohl, DE; Reichman, BS; Seidman, AD; Surbone, A | 1 |
| Chaudhry, V; Cornblath, DR; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; Lubejko, BG; Rowinsky, EK; Sartorius, SE | 1 |
| Arbuck, SG; Canetta, R; Christian, MC; Onetto, N | 1 |
| Champlin, R; Deisseroth, AB; Holmes, F; Hortobagyi, G | 1 |
| Andreotti, PE; Bruckner, HW; Cree, IA; Indefrei, D; Kurbacher, CM; Kurbacher, JA; Mallmann, P; Pöch, G; Wilhelm, L | 1 |
| Miller, KD; Sledge, GW | 1 |
| Belani, CP; Selvaggi, G | 1 |
| Barnett, D; Oldham, RK; Reid, WK | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Hortobagyi, GN | 1 |
| Adamo, DO; Cunnion, RE; Jacob, J; Kohn, E; Ognibene, FP; Reed, E; Rothenberg, M; Sarosy, G; Stone, DA | 1 |
4 review(s) available for paclitaxel and Bone Marrow Diseases
| Article | Year |
|---|---|
Current dosage and schedule issues in the development of paclitaxel (Taxol).
Topics: Animals; Bone Marrow Diseases; Clinical Trials as Topic; Dogs; Dose-Response Relationship, Drug; Drug Evaluation; Drug Evaluation, Preclinical; Drug Hypersensitivity; Humans; Mice; Microtubules; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Rats; Time Factors | 1993 |
Taxanes in the treatment of breast cancer: a prodigy comes of age.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Palliative Care; Survival Analysis; Taxoids; Tubulin; Vinca Alkaloids | 1999 |
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoprotection; Humans; Lung Neoplasms; Nervous System Diseases; Paclitaxel; Protective Agents; Randomized Controlled Trials as Topic | 1999 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
8 trial(s) available for paclitaxel and Bone Marrow Diseases
| Article | Year |
|---|---|
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infections; Infusions, Intravenous; Kaplan-Meier Estimate; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Salvage Therapy; Stomach Neoplasms | 2009 |
Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.
Topics: Adult; Aged; Bone Marrow Diseases; Carcinoma; Drug Administration Schedule; Drug Resistance; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 1994 |
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Topics: Aged; Bone Marrow Diseases; Drug Administration Schedule; Drug Hypersensitivity; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Musculoskeletal Diseases; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1994 |
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Bone Marrow Diseases; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Treatment Outcome | 1993 |
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Least-Squares Analysis; Male; Middle Aged; Neoplasms; Neuromuscular Diseases; Paclitaxel | 1993 |
Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Follow-Up Studies; Humans; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Remission Induction; Salvage Therapy; Treatment Outcome; Tumor Cells, Cultured | 1997 |
Phase I study of CBT-1 and Taxol in patients with Taxol resistant cancers.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Biological Factors; Bone Marrow Diseases; Combined Modality Therapy; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Humans; Hyperpigmentation; Male; Middle Aged; Neoplasms; Paclitaxel; Salvage Therapy; Treatment Outcome | 2000 |
Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Carcinoma; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1992 |
6 other study(ies) available for paclitaxel and Bone Marrow Diseases
| Article | Year |
|---|---|
Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Disease Models, Animal; Drug Administration Schedule; Female; Ganglia, Spinal; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Weight Loss | 2009 |
Factors affecting bone marrow toxicity following administration of carboplatin and paclitaxel in patients with non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Cells; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Retrospective Studies; Young Adult | 2010 |
[Analysis of relative factors of bone marrow suppression after chemotherapy with carboplatin and paclitaxel on the patients with ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Bone Marrow; Bone Marrow Diseases; Carboplatin; Creatinine; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2011 |
The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow Diseases; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Receptors, Granulocyte Colony-Stimulating Factor; Recurrence | 1993 |
Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Diseases; Breast Neoplasms; Carmustine; Cyclophosphamide; Defective Viruses; DNA, Complementary; DNA, Recombinant; Drug Resistance, Neoplasm; Ethics, Medical; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Interleukin-6; Mesna; Middle Aged; Paclitaxel; Pilot Projects; Recombinant Fusion Proteins; Retroviridae; Safety; Thiotepa | 1996 |
Overview of new treatments for breast cancer.
Topics: Animals; Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Diseases; Breast Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Hormone Antagonists; Humans; Immunologic Factors; Paclitaxel; Pyrazoles; Pyrazolones; Survival Analysis; Vinblastine; Vinorelbine | 1992 |